INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. METHODS: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters. RESULTS: We identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR-320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis. DISCUSSION: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261-269, 2018.
INTRODUCTION:Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. METHODS: We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALSpatients with clinical parameters. RESULTS: We identified 7 miRNAs (miR-192-5p, miR-192-3p, miR-1, miR-133a-3p, miR-133b, miR-144-5p, miR-19a-3p) that were upregulated and 6 miRNAs (miR-320c, miR-320a, let-7d-3p, miR-425-5p, miR-320b, miR-139-5p) that were downregulated in patients with ALS compared with healthy controls, patients with Alzheimer disease, and patients with multiple sclerosis. Changes in 4 miRNAs (miR-136-3p, miR-30b-5p, miR-331-3p, miR-496) correlated positively and change in 1 miRNA (miR-2110) correlated negatively with changes in clinical parameters in longitudinal analysis. DISCUSSION: Our findings identified serum miRNAs that can serve as biomarkers for ALS diagnosis and progression. Muscle Nerve 58: 261-269, 2018.
Authors: M Tomás-Camardiel; J L Venero; A J Herrera; R M De Pablos; J A Pintor-Toro; A Machado; J Cano Journal: J Neurosci Res Date: 2005-04-15 Impact factor: 4.164
Authors: Erica D Koval; Carey Shaner; Peter Zhang; Xavier du Maine; Kimberlee Fischer; Jia Tay; B Nelson Chau; Gregory F Wu; Timothy M Miller Journal: Hum Mol Genet Date: 2013-06-04 Impact factor: 6.150
Authors: Sophie Hawkins; Seema C Namboori; Ammarah Tariq; Catherine Blaker; Christine Flaxman; Nidhi S Dey; Peter Henley; Andrew Randall; Alessandro Rosa; Lawrence W Stanton; Akshay Bhinge Journal: Stem Cell Reports Date: 2022-06-23 Impact factor: 7.294
Authors: Keren Regev; Brian C Healy; Anu Paul; Camilo Diaz-Cruz; Maria Antonietta Mazzola; Radhika Raheja; Bonnie I Glanz; Pia Kivisäkk; Tanuja Chitnis; Maja Jagodic; Fredrik Piehl; Tomas Olsson; Mohsen Khademi; Stephen Hauser; Jorge Oksenberg; Samia J Khoury; Howard L Weiner; Roopali Gandhi Journal: Neurol Neuroimmunol Neuroinflamm Date: 2018-08-20